For four years, every first aid kit brand selling into Great Britain has carried a second compliance project in the background: UKCA marking. The domestic conformity route was created after Brexit, acceptance of EU CE marks was kept alive only through transitional arrangements with hard end dates — 30 June 2028 or 2030, depending on the legal basis — and the whole industry planned around a cliff edge that would have forced a duplicate conformity assessment for the British market alone.
That cliff edge is gone. On 21 October 2026, the UK government confirmed that medical devices and IVDs certified under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) will be recognised in Great Britain on an indefinite basis. The decision followed an MHRA consultation that ran from February to April 2026 and drew 1,056 responses from manufacturers, UK Responsible Persons, approved bodies, healthcare professionals and patient groups.
If you import first aid kits into the UK, this is the most consequential market-access decision since Brexit. Here is what was decided, what it does not change, and how we would re-plan a UK product line around it.
Three parts matter, and they are easy to blur together:
1. Indefinite recognition of CE marks. Devices certified under the EU MDR and IVDR can be placed on the GB market — England, Scotland and Wales — for as long as their CE certification remains valid. The previous end dates (30 June 2028 for MDR/IVDR devices in most categories, 2030 in others) will be removed by legislation. This matters enormously in practical terms: according to the MHRA, more than 90% of medical devices registered for use in Great Britain currently carry a CE mark. The decision protects the compliance model that nearly the entire market already runs on.
2. Alignment of MDD legacy timelines with the EU. Devices certified under the old Medical Devices Directive — the pre-MDR regime some older kit documentation still rests on — will be aligned with the EU's own transition timetable, which currently ends 31 December 2028, with an earlier 31 December 2027 date for certain higher-risk legacy devices. The government also chose not to take forward two consulted options: recognition will not be limited to devices in the same or lower risk class under GB rules, and there will be no separate reliance route for devices classified higher in GB than in the EU.
3. UKCA stays, as an option rather than a deadline. The domestic marking route remains available. Nothing about the decision prevents a manufacturer from seeking UKCA certification — it simply stops being the mandatory endgame for devices that hold valid EU certification.
One timing caveat that compliance teams must not gloss over: this is a confirmed policy decision, not yet law. Implementing legislation is intended before 30 June 2028 and is subject to parliamentary approval. Until the amendments enter into force, the existing transitional arrangements continue to govern. The direction of travel is now about as clear as regulation gets — but a compliance calendar should still cite the legislation, not the announcement, as the operative change.
The headlines celebrate the marking decision. The obligations that actually generate enforcement action are untouched:
MHRA registration remains mandatory. Every device placed on the GB market must be registered with the Medicines and Healthcare products Regulatory Agency before supply — including Class I kits, systems and procedure packs, and custom-made devices. The MHRA refreshed its registration guidance on 11 November 2026, and it restates the point that registration is not approval: no MHRA logo, no "MHRA certified" claim, no implying endorsement in marketing. For kit sellers, that means registration discipline — correct GMDN codes, UDI-DI where applicable, and updated records when your configurations change.
A UK Responsible Person is still required. Manufacturers established outside the UK must appoint a single UKRP for their GB portfolio. The UKRP registers devices with the MHRA and carries statutory compliance functions. This was never optional and remains so under the new policy. (One housekeeping note from the November guidance: DORS accounts belonging to former GB authorised representatives that had not converted to the UKRP role by 30 March 2026 have been closed — if your representative relationship changed in the last two years, verify your registration did not lapse with it.)
Northern Ireland runs on EU rules. Under the Windsor Framework, NI applies the EU MDR and IVDR, and since 28 May 2026 devices placed on the NI market register through EUDAMED rather than the MHRA — with the 27 November 2026 legacy registration deadline we covered separately. The practical geography for a kit brand: CE-MDR documentation now covers EU, NI and GB; GB adds an MHRA registration and UKRP on top; and a UKCA route remains optional for those who want it.
Post-market obligations continue. Vigilance, post-market surveillance and complaint handling apply to CE-marked kits in GB exactly as before.
Strip away the regulatory language and the decision delivers three commercial benefits:
One conformity assessment, three markets. An MDR-compliant first aid kit — Class I self-declared, or Class Is where sterile components are included — now serves the EU, Northern Ireland and Great Britain on the same technical file. Before this decision, a brand selling across the channel faced a real possibility of funding a parallel UKCA assessment by 2028. For a mid-size kit range, that duplication was a five-figure annual line item in compliance spend.
Product development simplifies. Kit configurations change constantly — a new tourniquet spec, a bilingual guide, a refreshed insert tray. Each change triggers documentation updates. Under the old regime, UK-bound variants risked diverging from EU variants as teams patched two systems. One recognition regime means one change-control path, and fewer opportunities for the GB version of your kit to drift out of sync with the EU version.
The compliance budget moves to product. Money and attention previously reserved for a duplicate UKCA project can go where buyers actually notice: BS 8599-1 conformance, trauma-kit extensions for the UK's heightened bleeding-control expectations, and packaging that survives retail handling. We covered the BS 8599-1:2026 amendment in detail — UK workplace buyers increasingly spec against it, and it is a product conversation, not a paperwork one.
If you are re-planning a UK range around the new reality — or consolidating EU and GB variants into one file — send us your current kit configurations, and we will map which components and documentation pieces serve all three markets unchanged and which need market-specific variants.
We already produced UKCA-marked stock. Do we have to scrap it?
No. UKCA marking remains a valid route for the GB market, and stock already bearing the mark is compliant as-is. The decision removes the future obligation, not the validity of what exists. If you hold dual-marked inventory, you now have flexibility: sell through the UKCA stock first in the UK, or hold it — either way nothing is stranded.
Does this mean we can ignore the UK entirely and ship one EU box everywhere?
Not quite. The conformity file is now one, but GB still requires MHRA registration, a UK Responsible Person, and GB-specific labelling practice — including the UK's own responsible-person details on packaging. The box can be the same; the registration and label data cannot be skipped.
Is our MDD-based CE certificate now fine forever?
No — this is the most common misreading. Indefinite recognition applies to devices certified under the EU MDR and IVDR. MDD legacy devices get their timelines aligned with the EU transition, which still closes on 31 December 2028 (earlier for some categories). An MDD file with a 2028 end date is not rescued by this decision; it just now has a known path: migrate to MDR, and the GB market follows the same file.
What should we do about artwork and claims on UK packaging?
Use the November registration guidance as the checklist: no MHRA logo, no "registered/approved by MHRA" phrasing, UKRP details present, and claims that match the technical file. Most of the packaging issues we see in UK-bound kits are claim wording, not marking.
As a manufacturer running CE documentation for UK and EU customers from the same Yiwu facility, here is the sequence we are advising for 2027 programmes:
1. Confirm the legal basis of every kit file. MDR-based files are the winners under the new policy — indefinite recognition. Files still resting on MDD certificates should migrate to MDR before the EU transition closes on 31 December 2028 (earlier for some legacy categories). The migration is a documentation project, not a redesign, but it has a real calendar.
2. Audit the UKRP and MHRA registration. The recognition decision changed nothing here, and registration lapses are the most common silent failure we see in UK-bound lines. Verify the UKRP appointment, the DORS registrations, and that every current SKU configuration is on file.
3. Re-check sterile component classification. If your kit includes sterile items, its Class Is status drives which conformity path and labeling rules apply in both the EU and GB. Classification errors surface at the worst times — during a retail onboarding audit or a customs query.
4. Decide deliberately about UKCA. Some UK distributors and institutional buyers may still ask for it; UKCA remains a legitimate route, particularly for brands that want a UK-specific mark for marketing reasons. But it is now a choice with a business case, not an obligation with a deadline.
5. Watch the implementing legislation. Between now and 30 June 2028, the statutory instruments that enact the decision will pass through Parliament. If any conditions are attached — documentation requirements, recognition scopes — your compliance calendar should pick them up then, not from headlines.
For buyers building new UK programmes in 2027, our standard terms apply: ISO 13485, CE, FDA and UKCA registered, roughly 100 people across 5,000 square meters in Yiwu, MOQ 500 units per SKU, about 30 days' standard lead time. We hold UKCA documentation capability alongside CE, so both routes stay open for customers who want them. If that is the kind of flexibility your range needs, request a quote from our export team — tell us your target markets and we will show you which single file covers them.
The UKCA cliff edge occupied four years of compliance planning. It is gone. The brands who notice first will spend that reclaimed budget on products their customers can actually see.
Further Reading
*Selling First Aid Kits in the UK in 2026: CE, UKCA and MHRA Reforms — the September baseline analysis, now updated with the October decision.
*BS 8599-1:2026: UK First Aid Kit Sizes, Contents and AEDs — what UK workplace buyers are now speccing against.
*EU MDR First Aid Kits: Classes, EUDAMED and 2027 Car Rules — the EU-side file your GB access now rides on.
Questions about UK market access for your kit range? Contact our export team — we reply within one business day.